Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

varicella zoster virus

- PMLiVE

FDA hands GSK a reprieve by blocking Novartis generic

The Advair rival could be delayed until 2019

- PMLiVE

Gilead’s triple HIV drug approval prompts GSK lawsuit

ViiV claims bictegravir infringes its patent estate

AstraZeneca AZ

AZ’s COPD triple data sets up market clash with GSK

KRONOS trial showed significant improvements in lung function tests over two-drug combos

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

- PMLiVE

GSK gets another approval for Nucala in US

Its antibody is first approved treatment for a rare and sometimes life-threatening vascular disease

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

- PMLiVE

EMA approves GSK’s triple COPD therapy

Trelegy can now be marketed as a maintenance treatment in Europe

- PMLiVE

Ex-GSK head Witty to head group overseeing UK fast-track scheme

Medicines selected for the AAP could be made available much earlier

- PMLiVE

GSK to replace R&D head Vallance with Calico’s Hal Barron

Barron will also hold an executive director position on GSK’s board

- PMLiVE

GSK’s R&D head Vallance departs, possibly for government role

An independent panel of scientists proposed the UK role to Vallance, according to the FT

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links